Abbott Laboratories stock reports Q2 growth and earnings beat

Abbott Laboratories stock was trading at USD 103.53 on the NYSE on September 23, 2026 at 3:59 p.m. ET, down 0.20 percent. The Q2 2026 report delivered revenue growth and an adjusted earnings beat, giving investors two different signals to weigh.

Q2 sales beat expectations

Abbott generated USD 12.59 billion in Q2 2026 revenue, an increase of 13.0 percent from the same quarter a year earlier, according to MarketBeat. Adjusted EPS reached USD 1.31, topping the USD 1.28 consensus by USD 0.03.

The accounting split matters. GAAP diluted EPS was USD 0.53 and net income attributable to common shareholders was USD 928 million in Q2 2026, while operating margin stood at 13.0 percent.

Guidance points to higher earnings

Abbott's full-year 2026 adjusted EPS guidance stands at USD 5.45 to USD 5.60, compared with the previous range of USD 5.38 to USD 5.58. The company also retained comparable sales growth guidance of 6.5 percent to 7.5 percent for 2026.

That guidance places the Q2 beat in a broader earnings framework rather than treating it as an isolated quarter. The gap between adjusted EPS of USD 1.31 and GAAP EPS of USD 0.53 also makes the quality and composition of earnings relevant for the next update.

Stock remains below yearly high

At USD 103.53, Abbott stock stood 24.3 percent below its 52-week high of USD 136.83 and 26.3 percent above its 52-week low of USD 81.97 on September 23, 2026. Market capitalization was USD 179,137,938,586 at the same snapshot.

A separate legal overhang remains quantifiable: Abbott agreed to pay USD 385 million in a September 14, 2026 settlement tied to claims involving its 2022 powdered infant formula recall, as StockTitan reported. For investors, the next valuation debate links the 13.0 percent sales increase with the sizable distance from the yearly high.